Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

Daily Edge Report Puts (NXL) At The Top Of Today's Watchlist—Tuesday, February 24, 2026

Don't miss the next breakout — get real-time alerts sent straight to your phone!

Full Coverage Starts Now.

Take A Look At (NXL) While It's Still Early…

February 24, 2026

Minutes to Go | See Why (NXL) Just Hit the Top of Today's Radar

Dear Reader,

In neurology and mental health, progress hasn't come from a single breakthrough, it's been incremental. Treatments may help manage symptoms, but for many patients, long-term relief remains difficult to achieve. That gap is driving increased attention toward alternative approaches designed to work at a deeper neurological level.

One company positioning itself within that shift is Nexalin Technology, Inc. (Nasdaq: NXL).

(NXL) is developing a non-invasive stimulation platform built around its proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology, designed to help regulate brain activity without the need for pharm-aceu-ticals or surgical intervention. The focus is on addressing complex conditions tied to neurological and mental health function, areas where demand for new solutions continues to grow.

That's one of the reasons (NXL) has moved onto our watchlist heading into Today's session—February 24, 2026.

From a structural standpoint, the float remains relatively limited. (NXL) has fewer than 15M shares available to the public. Lower float profiles can sometimes create amplified reactions when demand begins to shift.

Recent activity, (NXL) made an approximate 37% move inside of 3 days, from around $0.37 on February 17 to $0.51 on February 20, according to data available from Barchart. Moves like that don't happen in a vacuum, they often show up when a chart is waking up and supply-demand dynamics begin to tighten.

Despite that activity, (NXL) continues to trend below the $1 level, keeping it off many institutional screens and under broader market visibility.

However, it has not gone entirely unnoticed.

At least one firm has initiated coverage, placing a defined valuation outlook on the company from current levels.

Analyst Coverage Points to Significant Re-Rating Upside Potential

Coverage from Maxim Group includes a published target of $4 on (Nasdaq: NXL). Based on recent levels around the sub-$1 range, this suggests an upside potential of around 700%.

The outlook is tied to several factors, including (NXL)'s ongoing clinical development, expansion of its intellectual property portfolio, and progress toward broader commercialization and international market access.

As regulatory pathways, clinical milestones, and distribution efforts continue to evolve, the broader narrative is beginning to take shape. (Nasdaq: NXL) is a developing-stage medical technology profile operating within a high-demand segment, with multiple potential catalysts that could influence visibility moving forward.

A New Approach to Brain Health: Inside Nexalin's Technology

Nexalin Technology, Inc. (Nasdaq: NXL) is a medical device company focused on advancing non-invasive solutions for neurological and mental health conditions. Its approach centers on neuromodulation, using targeted stimulation to influence brain activity without the need for pharm-aceu-ticals or invasive procedures.

At the core of the company's platform is its proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology. This system is designed to deliver specific frequency-based stimulation intended to interact with brainwave patterns and support neurological balance. The company's approach is aimed at addressing conditions such as anxiety, insomnia, and depression, areas where many patients continue to seek alternative treatment options.

Nexalin's product line includes its Generation 2 (Gen-2) device, which is being evaluated for clinical applications, as well as its Generation 3 (Gen-3) system, which is designed to expand capabilities and support broader commercialization efforts in international markets.

The company is also focused on expanding its intellectual property portfolio and advancing regulatory milestones, including clearances and approvals that may support adoption across multiple regions.

By focusing on non-invasive neuromodulation, Nexalin is positioning itself within a growing segment of healthcare that is exploring alternatives to traditional dr-ug-based therapies, particularly for complex neurological and mental health conditions.

Positioned Within Expanding Multi-Bn Dollar Markets

The landscape for neurological and mental health treatment is continuing to evolve, driven by rising diagnosis rates, aging populations, and growing demand for alternative therapies. As a result, multiple adjacent markets tied to brain health are projected to see sustained long-term growth.

Within that broader shift, neuromodulation is emerging as a key area of focus. Industry forecasts estimate the neuromodulation market could reach approximately $11B by 2028, reflecting increasing adoption of technologies designed to directly influence brain activity.

Zooming out further, the total global mental health market is projected to approach $573B by 2033, highlighting the scale of unmet need across a wide range of neurological and psychiatric conditions.

Nexalin's development strategy is centered on targeting some of the more complex areas within this landscape, particularly conditions where current treatment options may not deliver consistent or durable outcomes.

One of those areas is neurodegeneration. Alzheimer's disease, for example, represents a global market often estimated in excess of $10B, driven largely by demographic trends and limited treatment alternatives. Nexalin has taken initial steps into this space, including a recent FDA Q-Submission for its Gen-2 SYNC device in Alzheimer's, which could help define a future regulatory pathway.

In addition to neurodegenerative disorders, the company is also exploring applications in Attention Deficit Hyperactivity Disorder (ADHD), a condition estimated to affect approximately 4–5% of adults worldwide.

A peer-reviewed study published in Molecular Psychiatry reported that Nexalin's technology demonstrated the ability to normalize certain patterns of brain activity in ADHD patients. If further validated, this approach could position the company within a treatment market that is also commonly sized above $10B and has historically relied on stimulant-based medications.

Taken together, these efforts place Nexalin within several large and expanding healthcare segments, where new approaches to treatment are actively being explored.

Recent Developments Putting (Nasdaq: NXL) on the Radar

Nexalin Technology (Nasdaq: NXL) has continued to release a steady stream of updates across clinical research, commercialization, and platform expansion, pointing to active development across multiple fronts.

AI Virtual Clinic Launch Expands Access Model: (NXL) recently announced the launch of NeuroCare®, an AI-driven virtual clinic platform developed in collaboration with the University of California, San Diego. The platform integrates Nexalin's Gen-3 HALO device to enable remote, physician-monitored treatment, potentially reducing barriers to care and expanding patient access beyond traditional clinic settings.

Peer-Reviewed Research Supports Technology Platform (Feb 2026)
Nexalin highlighted an expanding body of peer-reviewed neuroimaging research demonstrating its ability to modulate deep brain networks across multiple conditions, including insomnia, depression, PTSD, ADHD, Alzheimer's disease, and addiction-related disorders.

FDA Engagement Advances Alzheimer's Program: (NXL) completed a formal FDA Q-Submission meeting for its Gen-2 SYNC device targeting Alzheimer's disease, with the FDA providing guidance on clinical study design and a potential regulatory pathway. This builds on earlier acceptance of the submission and helps define next steps toward U.S. clinical development.

International Expansion Through Distribution Agreement: Nexalin entered into an exclusive distribution agreement in Israel following regulatory clearance from the Israeli Ministry of Health. The agreement enables commercialization of its Gen-2 SYNC device for conditions such as insomnia, depression, and anxiety, while also supporting expansion into additional indications.

Media Exposure & Awareness: Nexalin was featured on the RedChip "Small Stocks, Big Money" show, which airs on Bloomberg TV and reaches millions of households—potentially increasing visibility.

7 Reasons (NXL) Is on Our Watchlist Heading Into Today's Session

Analyst Coverage Highlights Valuation Gap: Maxim Group has issued a $4 target on (Nasdaq: NXL). Based on recent sub-$1 levels, that reflects around 700% upside potential.
Low Float Structure: With fewer than 15M shares in the public float, (NXL) has a structure where shifts in demand and attention could translate into amplified movement.
Recent Momentum: An approximate 37% move in just three days recently pushed (NXL) from about $0.37 to $0.51, signaling renewed activity on the chart.
FDA Engagement in Alzheimer's Program: (NXL) recently completed a Q-Submission meeting with the FDA for its Gen-2 SYNC device targeting Alzheimer's disease, helping define a potential U.S. clinical pathway in a market often estimated above $10B.
Expanding Clinical and Research Foundation: Peer-reviewed findings, including publications in Molecular Psychiatry, have demonstrated Nexalin's ability to modulate brain activity across multiple indications, including ADHD and neurodegenerative conditions.
AI-Driven Platform Expansion: The recent launch of NeuroCare®, an AI-enabled virtual clinic model, introduces a new pathway for remote, physician-guided treatment—potentially expanding patient access and scalability.
International Commercial Footprint Growing: Regulatory clearance and distribution agreements in markets such as Israel are supporting early-stage global expansion, alongside a broader pipeline spanning depression, insomnia, addiction, and neurological disorders.

Take A Look At (NXL) While It's Still Early…

The broader setup surrounding Nexalin Technology, Inc. (Nasdaq: NXL) points to a company operating at the intersection of clinical development, expanding market demand, and evolving treatment approaches in neurological care. With a public float of fewer than 15M shares, the structure remains relatively tight, which can become a factor if interest and demand begins to shift.

From a valuation perspective, published coverage from Maxim Group includes a $4 target. Based on recent sub-$1 levels, that represents a significant percentage gap between current levels and the analyst's modeled outlook.

At the same time, (NXL) continues to advance across several key areas. Recent FDA engagement through its Alzheimer's Q-Submission helps define a potential U.S. clinical pathway into a market often estimated above $10B. Peer-reviewed findings, including research published in Molecular Psychiatry, continue to support the underlying technology's ability to influence brain activity across multiple indications.

Beyond clinical progress, (NXL) is also expanding its commercial and delivery model. The introduction of its AI-driven NeuroCare® platform, alongside early international expansion through regulatory clearances and distribution agreements, reflects a broader effort to scale access to its non-invasive technology.

Taken together, the story continues to develop across clinical, regulatory, and commercial fronts.

We have all eyes on (NXL) this morning.

Take a look at (NXL) while it's still early.

Also, keep a lookout for our next update, it could be here very shortly.

Sincerely,

Joel Locke

Senior Editor

The Daily Edge Report

^{DailyEdgeReport.com}^{("DailyEdgeReport" or "DER" ) is owned by GG Media Holdings LLC, a single member limited liability company. Data is provided from third-party sources and DER is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile DER brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.}

_{Pursuant to an agreement between GG Media Holdings LLC and TD Media LLC, GG Media Holdings LLC has been hired for a period beginning on 02/23/2026 and ending on 02/24/2026 to publicly disseminate information about (NXL:US) via digital communications. Under this agreement, TD Media LLC has paid GG Media Holdings LLC seven thousand five hundred USD ("Funds"). These Funds were part of the seventy seven thousand five hundred USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

_{Neither GG Media Holdings LLC, TD Media LLC and their member own shares of (NXL:US).}

_{Please see important disclosure information here:}_{https://dailyedgereport.com/disclosure/nxl-2uAde/#details}